Article Text

Download PDFPDF
Cough and upper airway disorders in elite athletes: a critical review
  1. Louis-Philippe Boulet
  1. Correspondence to Louis-Philippe Boulet, Department of Pneumology, Institut universitaire de cardiologie et de pneumologie de Québec, 2725, Chemin Ste-Foy, Québec, Quebec, Canada, G1V 4G5; lpboulet{at}


Respiratory diseases such as asthma, chronic cough, recurrent respiratory infections and various upper airways conditions are common in elite athletes, but these conditions are often underdiagnosed and undertreated. Recurrent cough, often observed after exercise, is the most commonly reported symptom in athletes, particularly winter athletes, but it does not predict airway function; its intensity correlates with the dryness of inspired air but may not be associated with airway hyper-responsiveness. Rhinitis, either allergic or not, is highly prevalent in athletes, particularly non-allergic rhinitis in swimmers. Finally, dysfunctional breathing, including vocal cord dysfunction, may mimic or accompany asthma in a significant number of athletes. These conditions should be recognised and treated properly according to current guidelines, although how these last apply in the athlete is uncertain. Furthermore, regulatory agencies' restrictions on the type of drugs allowed for therapeutic use of these conditions in competitive athletes should be checked.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Competing interests Disclosure of potential conflicts of interest of L.-P. Boulet. Advisory Boards: AstraZeneca, GlaxoSmithKline, Merck Frosst and Novartis. Lecture fees: 3M, AstraZeneca, GlaxoSmithKline, Merck Frosst and Novartis. Sponsorship for investigator-generated research: AstraZeneca, GSK, Merck Frosst and Schering. Research funding for participating in multicentre studies: Altair, Asmacure, AstraZeneca, Boehringer-Ingelheim, Genentech, GlaxoSmithKline, Pharmaxis, Schering, Wyeth. Support for the production of educational materials: AstraZeneca, GlaxoSmithKline and Merck Frosst. Governmental: Adviser for the Conseil du Médicament du Québec, AETMIS. Organisational: Chair of the Canadian Thoracic Society Respiratory Guidelines Committee and chair of GINA Guidelines Dissemination and Implementation Committee. Holder of the Laval University Chair on Knowledge Transfer, Prevention and Education in Respiratory and Cardiovascular Health. Member of the Knowledge Translation (KT Canada) supported by the CIHR.

  • Provenance and peer review Not commissioned; externally peer reviewed.